News \ Insights

Guest Post: The Symbiosis of Regulation and Science – Óskare Capital SAS

ÓSKARE Fund I & Medical Cannabinoids

Hauck & Aufhäuser analyse Europe’s Medical Cannabis market and Óskare Capital’s role within it:

Thanks to progressive regulation, especially in Europe, a new market has developed in recent years which is solely dedicated to research into cannabis-like active ingredients that effect the Endocannabinoid System, for medical purposes. ÓSKARE Fund I launched in June 2020 and the Paris-based company ÓSKARE Capital is now offering the world’s first AIFM- and ESG-compatible fund that invests in science and services related to the Endocannabinoid System.

Fund I, which is based in Dublin and therefore deliberately located within the borders of the EU, expressly does not invest in opportunities that are related to the market for “recreational cannabis”. or cannabis production. Rather, scientific innovation approaches are specifically sought along the entire value chain, explore the cannabinoid molecules and their use as hemp biomass for medical and therapeutic purposes.

The focus is primarily on growth companies with oncological, neurological and cardiovascular-related focusses that are investigating the healing or relieving potential of molecules that target the Endocannabinoid System in cancer, depression, epilepsy, anxiety, sleep disorders. and more.

The fund is making use of the regulatory uniformity and consistency of the European market for cannabinoid research and is relying on the already recognizable strong growth of the sector,  with a first successful investment in the Danish company Octarine Bio.

Investments in such a highly diversified and disruptive area require special know-how and the ÓSKARE team has many years of expertise at the interface between the fields of agricultural engineering, chemistry, medicine, venture capital and the protection of intellectual property.

Company co-founder Bruce Linton developed Canopy Growth as CEO and founder, the cannabis producer which celebrated its NASDAQ debut in 2018. The investment process is also supported by an experienced team of experts made up of executives from the pharmaceutical, agricultural and medical industries, providing a strong network of leading researchers in these areas. Investments in European innovation – for global health.